1. Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
   Dajeong Lee et al, 2020, Biomolecules & Therapeutics CrossRef
2. Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK Pathways
   Eun Hye Lee et al, 2022, International Journal of Molecular Sciences CrossRef
3. Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
   Niamh McGivern et al, 2018, Oncotarget CrossRef
4. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs
   Melita Moioli et al, 2019, Expert Opinion on Investigational Drugs CrossRef
5. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells
   Ulla-Maija Haltia et al, 2017, Gynecologic Oncology CrossRef
6. Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells
   Ling Ma et al, 2019, Cancer Biology & Therapy CrossRef
7. FYN: emerging biological roles and potential therapeutic targets in cancer
   SanFei Peng et al, 2023, Journal of Translational Medicine CrossRef
8. Targeting the Extra-Cellular Matrix—Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors
   Girieca Lorusso et al, 2020, Frontiers in Oncology CrossRef
9. Interplay between paclitaxel, gap junctions, and kinases: unraveling mechanisms of action and resistance in cancer therapy
   Dong-Oh Moon, 2024, Molecular Biology Reports CrossRef
10. miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2
    Youngmi Kim et al, 2016, Oncotarget CrossRef
11. Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
    Elif Kadife et al, 2019, Cancers CrossRef
12. Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer
    Na Li et al, 2021, Frontiers in Genetics CrossRef
13. Network controllability solutions for computational drug repurposing using genetic algorithms
    Victor-Bogdan Popescu et al, 2022, Scientific Reports CrossRef
14. Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer
    Anusha Ande et al, 2018, Frontiers in Pharmacology CrossRef
15. Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
    Eri Takiguchi et al, 2017, Experimental and Therapeutic Medicine CrossRef
16. Deciphering Biophysical Modulation in Ovarian Cancer Cells
    Makhdoom Sarwar et al, 2021, Cell Biochemistry and Biophysics CrossRef
17. Synergistic Anti-Tumor Effect of Palmitoylcarnitine and Dasatinib in Liver Cancer
    Ragini Singh et al, 2022, Livers CrossRef
18. c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
    Stefania Belli et al, 2020, Cancers CrossRef
19. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
    Soozana Puvanenthiran et al, 2016, International Journal of Oncology CrossRef
20. Mechanisms of Taxane Resistance
    Sara M. Maloney et al, 2020, Cancers CrossRef
21. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy
    Jingjing Sun et al, 2017, Journal of Controlled Release CrossRef